Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Gilead Licenses Long-Acting HIV Prevention Drug
Gilead Licenses Long-Acting HIV Prevention Drug to Generics Firms
Gilead Sciences Inc. said it is licensing its twice-yearly experimental HIV prevention drug lenacapavir to six generics makers after coming under fire from HIV advocates who argued the company was prioritizing profit over patients.
Gilead signs deals with 6 generic drugmakers to sell HIV drug in low-income countries
Gilead Sciences said on Wednesday it has granted royalty-free licenses to six generic drug manufacturers to make and sell cheaper copycat versions of its HIV prevention medicine in 120 low and lower-middle income countries.
Gilead strikes deal to expand HIV drug access in 120 countries
If approved, the six manufacturers – Dr Reddy’s Laboratories Limited, Emcure, Eva Pharma, Ferozsons Laboratories Limited, Hetero, and Mylan (a subsidiary of Viatris) – will be able to produce and distribute generic versions of lenacapavir without paying royalties to Gilead.
Gilead Partners With Generics Developers to Provide HIV Drug to Low-Income Countries
Gilead Sciences is granting licenses to six companies to produce lenacapavir for pre-exposure prophylaxis, as well as for treating human immunodeficiency virus in heavily pre-treated adults with multidrug-resistant infections.
Gilead strikes voluntary licensing deals in poor countries for its pricey HIV drug
Gilead will license the HIV drug lenacapavir, a twice-yearly injectable, to six generic makers for 120 countries.
Gilead strikes licensing deals with 6 generics makers to boost access to long-acting HIV PrEP med
Gilead Sciences is wasting no time in promoting worldwide access to its twice-yearly pre-exposure prophylaxis (PrEP) HIV candidate lenacapavir. | The company will allow six generic manufacturers to make and sell its long-acting PrEP drug,
Gilead expands access to PrEP HIV candidate in 120 countries
A new licensing agreement from Gilead Sciences and six generic drug manufacturers is poised to transform HIV prevention efforts
HIV prevention: why a new injectable drug could be such a breakthrough – podcast
HIV expert Linda-Gail Bekker talks to The Conversation Weekly about promising results from a trial of a new drug for HIV prevention.
Biopharma firm Gilead announces lenacapavir licensing for HIV treatment
International AIDS Society, an association of HIV/AIDS professionals, applauded moves by Gilead Sciences, a biopharma company, to make the generic injectable lenacapavir for HIV prevention widely available, but cautioned that the current agreements still leave out millions around the world.
Gilead Licenses HIV-prevention Drug To Generic Drugmakers
US pharmaceutical giant Gilead said Wednesday it had signed licensing deals with six generic drugmakers to produce and sell its HIV prevention medicine in lower-income countries.
GILD Grants Right for HIV PrEP Candidate to Six Generic Companies
Gilead Sciences GILD has entered into licensing deals with six pharmaceutical companies to manufacture and supply a cheaper version of its investigational drug, lenacapavir, for HIV prevention, also called pre-exposure prophylaxis (PrEP).
India Infoline
3h
Hetero Partners with Gilead to Expand Global Access to HIV Drug Lenacapavir
The collaboration supports efforts for HIV prevention through PrEP, emphasizing Hetero’s commitment to improving HIV care.
16h
Gilead inks pact with six generic drugmakers on long-acting HIV injectable, even as civil society oppose patent application
Six drugmakers sign agreements with Gilead Sciences to produce generic lenacapavir, a long-acting HIV drug, amid patent ...
1d
Ferozsons Partners With Gilead Sciences to Produce HIV Medicine in Pakistan
Ferozsons Laboratories Limited (PSX: FEROZ) has entered into a non-exclusive voluntary license agreement with Gilead Sciences ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Trending now
US port strike ends
Helene's wake
Sentenced to 9 yrs in prison
Ex-Memphis cops guilty
Accused of sexual assault
California gang busted
5 Chinese nationals charged
OH gov. declares emergency
Golf Hall of Famer dies
US diagnostic errors study
Kirk becomes Category 4
Weekly jobless claims rise
To be closed indefinitely
CA deepfakes law blocked
Expands online recruitment
TikTok star charged
Secures $4 billion credit line
Freed from Gaza captivity
Record heat bakes millions
FDA: No longer in shortage
Fruit fly brain mapped
'Rust' gets premiere date
Israel strikes central Beirut
Student loan plan ruling
To hire 250,000 workers
Fifth recall within a year
Dream fire coach Wright
Mortgage rate ticks up
US bans 2 Chinese firms
Disrupt Russian hackers
Surveys Helene damage
Nevada politician guilty
Texas AG sues TikTok
India, US sign minerals pact
First mpox test approved
Wreck of WWII ship found
Feedback